Clinical Applications of Diffusion MR Imaging for Acute Ischemic Stroke

Neuroimaging Clinics of North America

Volumn 21, Issue 1, 2011, Pages 51-69

  Yoo, Albert J ^a   González, R Gilberto ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acute ischemic stroke; Diffusion MR imaging; Intra arterial reperfusion therapy; Intravenous reperfusion therapy

Indexed keywords

ALTEPLASE; DESMOTEPLASE; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD VESSEL OCCLUSION; BRAIN INFARCTION; BRAIN ISCHEMIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DRUG DOSE COMPARISON; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; REPERFUSION; REVIEW; TISSUE INJURY; TREATMENT INDICATION; TREATMENT RESPONSE;

ACUTE DISEASE; BRAIN; BRAIN ISCHEMIA; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; REPERFUSION; STROKE; TIME FACTORS;

EID: 79953306853     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2011.02.002     Document Type: Review

References (123)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):e21-e181.
2. Hacke W., Kaste M., Bluhmki E., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359(13):1317-1329.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995, 333(24):1581-1587.
4. Furlan A., Higashida R., Wechsler L., et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999, 282(21):2003-2011.
5. Rha J.H., Saver J.L. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007, 38(3):967-973.
6. Lo E.H., Dalkara T., Moskowitz M.A. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003, 4(5):399-415.
7. Mintorovitch J., Yang G.Y., Shimizu H., et al. Diffusion-weighted magnetic resonance imaging of acute focal cerebral ischemia: comparison of signal intensity with changes in brain water and Na+, K(+)-ATPase activity. J Cereb Blood Flow Metab 1994, 14(2):332-336.
8. Sykova E., Svoboda J., Polak J., et al. Extracellular volume fraction and diffusion characteristics during progressive ischemia and terminal anoxia in the spinal cord of the rat. J Cereb Blood Flow Metab 1994, 14(2):301-311.
9. Wick M., Nagatomo Y., Prielmeier F., et al. Alteration of intracellular metabolite diffusion in rat brain in vivo during ischemia and reperfusion. Stroke 1995, 26(10):1930-1933. [discussion: 1934].
10. Mullins M.E., Schaefer P.W., Sorensen A.G., et al. CT and conventional and diffusion-weighted MR imaging in acute stroke: study in 691 patients at presentation to the emergency department. Radiology 2002, 224(2):353-360.
11. Gonzalez R.G., Schaefer P.W., Buonanno F.S., et al. Diffusion-weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. Radiology 1999, 210(1):155-162.
12. Fiebach J.B., Schellinger P.D., Jansen O., et al. CT and diffusion-weighted MR imaging in randomized order: diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke 2002, 33(9):2206-2210.
13. Heiss W.D., Sobesky J., Smekal U., et al. Probability of cortical infarction predicted by flumazenil binding and diffusion-weighted imaging signal intensity: a comparative positron emission tomography/magnetic resonance imaging study in early ischemic stroke. Stroke 2004, 35(8):1892-1898.
14. Mohr J.P., Biller J., Hilal S.K., et al. Magnetic resonance versus computed tomographic imaging in acute stroke. Stroke 1995, 26(5):807-812.
15. Chalela J.A., Kidwell C.S., Nentwich L.M., et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 2007, 369(9558):293-298.
16. Fiebach J., Jansen O., Schellinger P., et al. Comparison of CT with diffusion-weighted MRI in patients with hyperacute stroke. Neuroradiology 2001, 43(8):628-632.
17. Grant P.E., He J., Halpern E.F., et al. Frequency and clinical context of decreased apparent diffusion coefficient reversal in the human brain. Radiology 2001, 221(1):43-50.
18. Kidwell C.S., Saver J.L., Starkman S., et al. Late secondary ischemic injury in patients receiving intraarterial thrombolysis. Ann Neurol 2002, 52(6):698-703.
19. Schaefer P.W., Hassankhani A., Putman C., et al. Characterization and evolution of diffusion MR imaging abnormalities in stroke patients undergoing intra-arterial thrombolysis. AJNR Am J Neuroradiol 2004, 25(6):951-957.
20. Kidwell C.S., Saver J.L., Mattiello J., et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000, 47(4):462-469.
21. Fiehler J., Knudsen K., Kucinski T., et al. Predictors of apparent diffusion coefficient normalization in stroke patients. Stroke 2004, 35(2):514-519.
22. Arenillas J.F., Rovira A., Molina C.A., et al. Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke. Stroke 2002, 33(9):2197-2203.
23. Olivot J.M., Mlynash M., Thijs V.N., et al. Relationships between cerebral perfusion and reversibility of acute diffusion lesions in DEFUSE: insights from RADAR. Stroke 2009, 40(5):1692-1697.
24. Chalela J.A., Kang D.W., Luby M., et al. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol 2004, 55(1):105-112.
25. Latchaw R.E., Alberts M.J., Lev M.H., et al. Recommendations for imaging of acute ischemic stroke. A scientific statement from the American Heart Association. Stroke 2009, 40(11):3646-3678.
26. Schellinger P.D., Bryan R.N., Caplan L.R., et al. Evidence-based guideline: the role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010, 75(2):177-185.
27. Clark W.M., Albers G.W., Madden K.P., et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 2000, 31(4):811-816.
28. Clark W.M., Wissman S., Albers G.W., et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999, 282(21):2019-2026.
29. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274(13):1017-1025.
30. Hacke W., Kaste M., Fieschi C., et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998, 352(9136):1245-1251.
31. Schellinger P.D., Thomalla G., Fiehler J., et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 2007, 38(10):2640-2645.
32. Thomalla G., Schwark C., Sobesky J., et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006, 37(3):852-858.
33. Kohrmann M., Juttler E., Fiebach J.B., et al. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol 2006, 5(8):661-667.
34. Ribo M., Molina C.A., Rovira A., et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005, 36(3):602-606.
35. Reddrop C., Moldrich R.X., Beart P.M., et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005, 36(6):1241-1246.
36. Liberatore G.T., Samson A., Bladin C., et al. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003, 34(2):537-543.
37. Hacke W., Albers G., Al-Rawi Y., et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005, 36(1):66-73.
38. Furlan A.J., Eyding D., Albers G.W., et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006, 37(5):1227-1231.
39. Albers G.W., Thijs V.N., Wechsler L., et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006, 60(5):508-517.
40. Kane I., Sandercock P., Wardlaw J. Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to date. J Neurol Neurosurg Psychiatry 2007, 78(5):485-491.
41. Schabitz W.R. MR mismatch is useful for patient selection for thrombolysis: no. Stroke 2009, 40(8):2908-2909.
42. Mishra N.K., Albers G.W., Davis S.M., et al. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke 2010, 41(1):e25-e33.
43. Hacke W., Furlan A.J., Al-Rawi Y., et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009, 8(2):141-150.
44. Davis S.M., Donnan G.A., Parsons M.W., et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008, 7(4):299-309.
45. Rivers C.S., Wardlaw J.M., Armitage P.A., et al. Do acute diffusion- and perfusion-weighted MRI lesions identify final infarct volume in ischemic stroke?. Stroke 2006, 37(1):98-104.
46. Kane I., Carpenter T., Chappell F., et al. Comparison of 10 different magnetic resonance perfusion imaging processing methods in acute ischemic stroke: effect on lesion size, proportion of patients with diffusion/perfusion mismatch, clinical scores, and radiologic outcomes. Stroke 2007, 38(12):3158-3164.
47. Davis S.M., Donnan G.A. MR mismatch and thrombolysis: appealing but validation required. Stroke 2009, 40(8):2910.
48. Butcher K.S., Parsons M., MacGregor L., et al. Refining the perfusion-diffusion mismatch hypothesis. Stroke 2005, 36(6):1153-1159.
49. Christensen S., Mouridsen K., Wu O., et al. Comparison of 10 perfusion MRI parameters in 97 sub-6-hour stroke patients using voxel-based receiver operating characteristics analysis. Stroke 2009, 40(6):2055-2061.
50. Kakuda W., Lansberg M.G., Thijs V.N., et al. Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients. J Cereb Blood Flow Metab 2008, 28(5):887-891.
51. Donnan G.A., Baron J.C., Ma H., et al. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol 2009, 8(3):261-269.
52. Coutts S.B., Simon J.E., Tomanek A.I., et al. Reliability of assessing percentage of diffusion-perfusion mismatch. Stroke 2003, 34(7):1681-1683.
53. Toth G., Albers G.W. Use of MRI to estimate the therapeutic window in acute stroke: is perfusion-weighted imaging/diffusion-weighted imaging mismatch an EPITHET for salvageable ischemic brain tissue?. Stroke 2009, 40(1):333-335.
54. Parsons M.W., Christensen S., McElduff P., et al. Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab 2010, 30(6):1214-1225.
55. Smith W.S., Lev M.H., English J.D., et al. Significance of large vessel intracranial occlusion causing acute ischemic stroke and TIA. Stroke 2009, 40(12):3834-3840.
56. Smith W.S., Tsao J.W., Billings M.E., et al. Prognostic significance of angiographically confirmed large vessel intracranial occlusion in patients presenting with acute brain ischemia. Neurocrit Care 2006, 4(1):14-17.
57. Sims J.R., Rordorf G., Smith E.E., et al. Arterial occlusion revealed by CT angiography predicts NIH stroke score and acute outcomes after IV tPA treatment. AJNR Am J Neuroradiol 2005, 26(2):246-251.
58. Davis S.M., Donnan G.A. Basilar artery thrombosis: recanalization is the key. Stroke 2006, 37(9):2440.
59. Maas M.B., Furie K.L., Lev M.H., et al. National Institutes of Health Stroke Scale score is poorly predictive of proximal occlusion in acute cerebral ischemia. Stroke 2009, 40(9):2988-2993.
60. Cipriano L.E., Steinberg M.L., Gazelle G.S., et al. Comparing and predicting the costs and outcomes of patients with major and minor stroke using the Boston Acute Stroke Imaging Scale neuroimaging classification system. AJNR Am J Neuroradiol 2009, 30(4):703-709.
61. Staroselskaya I.A., Chaves C., Silver B., et al. Relationship between magnetic resonance arterial patency and perfusion-diffusion mismatch in acute ischemic stroke and its potential clinical use. Arch Neurol 2001, 58(7):1069-1074.
62. Arnold M., Nedeltchev K., Brekenfeld C., et al. Outcome of acute stroke patients without visible occlusion on early arteriography. Stroke 2004, 35(5):1135-1138.
63. Arnold M., Nedeltchev K., Mattle H.P., et al. Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions. J Neurol Neurosurg Psychiatry 2003, 74(6):739-742.
64. Eckert B., Kucinski T., Neumaier-Probst E., et al. Local intra-arterial fibrinolysis in acute hemispheric stroke: effect of occlusion type and fibrinolytic agent on recanalization success and neurological outcome. Cerebrovasc Dis 2003, 15(4):258-263.
65. Barreto A.D., Albright K.C., Hallevi H., et al. Thrombus burden is associated with clinical outcome after intra-arterial therapy for acute ischemic stroke. Stroke 2008, 39(12):3231-3235.
66. Tan I.Y., Demchuk A.M., Hopyan J., et al. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. AJNR Am J Neuroradiol 2009, 30(3):525-531.
67. Zaidat O.O., Suarez J.I., Santillan C., et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke 2002, 33(7):1821-1826.
68. Gupta R., Vora N.A., Horowitz M.B., et al. Multimodal reperfusion therapy for acute ischemic stroke: factors predicting vessel recanalization. Stroke 2006, 37(4):986-990.
69. Fiehler J., Knudsen K., Thomalla G., et al. Vascular occlusion sites determine differences in lesion growth from early apparent diffusion coefficient lesion to final infarct. AJNR Am J Neuroradiol 2005, 26(5):1056-1061.
70. Nakano S., Iseda T., Kawano H., et al. Correlation of early CT signs in the deep middle cerebral artery territories with angiographically confirmed site of arterial occlusion. AJNR Am J Neuroradiol 2001, 22(4):654-659.
71. Liebeskind D.S. Collateral circulation. Stroke 2003, 34(9):2279-2284.
72. Derex L., Hermier M., Adeleine P., et al. Influence of the site of arterial occlusion on multiple baseline hemodynamic MRI parameters and post-thrombolytic recanalization in acute stroke. Neuroradiology 2004, 46(11):883-887.
73. Kucinski T., Naumann D., Knab R., et al. Tissue at risk is overestimated in perfusion-weighted imaging: MR imaging in acute stroke patients without vessel recanalization. AJNR Am J Neuroradiol 2005, 26(4):815-819.
74. Yoo A.J., Verduzco L.A., Schaefer P.W., et al. MRI-based selection for intra-arterial stroke therapy: value of pretreatment diffusion-weighted imaging lesion volume in selecting patients with acute stroke who will benefit from early recanalization. Stroke 2009, 40(6):2046-2054.
75. Gasparotti R., Grassi M., Mardighian D., et al. Perfusion CT in patients with acute ischemic stroke treated with intra-arterial thrombolysis: predictive value of infarct core size on clinical outcome. AJNR Am J Neuroradiol 2009, 30(4):722-727.
76. Baird A.E., Dambrosia J., Janket S., et al. A three-item scale for the early prediction of stroke recovery. Lancet 2001, 357(9274):2095-2099.
77. Sato S., Toyoda K., Uehara T., et al. Baseline NIH stroke scale score predicting outcome in anterior and posterior circulation strokes. Neurology 2008, 70(24 Pt 2):2371-2377.
78. Yoo A.J., Barak E.R., Copen W.A., et al. Combining acute diffusion-weighted imaging and mean transmit time lesion volumes with National Institutes of Health Stroke Scale Score improves the prediction of acute stroke outcome. Stroke 2010, 41(8):1728-1735.
79. DeGraba T.J., Hallenbeck J.M., Pettigrew K.D., et al. Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials. Stroke 1999, 30(6):1208-1212.
80. Ebinger M., Christensen S., De Silva D.A., et al. Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point. Stroke 2009, 40(4):1353-1358.
81. Warach S., Pettigrew L.C., Dashe J.F., et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 2000, 48(5):713-722.
82. Barrett K.M., Ding Y.H., Wagner D.P., et al. Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: results of the Acute Stroke Accurate Prediction (ASAP) trial serial imaging substudy. Stroke 2009, 40(7):2422-2427.
83. Hakimelahi R, Romero J, Nogueira RG, et al. Final infarct volume is the best predictor of outcome in large vessel occlusion patients treated with IAT. Paper presented at: American Society of Neuroradiology. Vancouver (BC), May 16-21, 2009.
84. Baron J.C. Perfusion thresholds in human cerebral ischemia: historical perspective and therapeutic implications. Cerebrovasc Dis 2001, 11(Suppl 1):2-8.
85. Ginsberg M.D., Pulsinelli W.A. The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke. Ann Neurol 1994, 36(4):553-554.
86. Hossmann K.A. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994, 36(4):557-565.
87. Astrup J., Siesjo B.K., Symon L. Thresholds in cerebral ischemia-the ischemic penumbra. Stroke 1981, 12(6):723-725.
88. Soares B.P., Tong E., Hom J., et al. Reperfusion is a more accurate predictor of follow-up infarct volume than recanalization. A proof of concept using CT in acute ischemic stroke patients. Stroke 2010, 41(1):e34-40.
89. Hermier M., Nighoghossian N., Adeleine P., et al. Early magnetic resonance imaging prediction of arterial recanalization and late infarct volume in acute carotid artery stroke. J Cereb Blood Flow Metab 2003, 23(2):240-248.
90. Caplan L.R. Stroke thrombolysis: slow progress. Circulation 2006, 114(3):187-190.
91. King S., Khatri P., Carrozella J., et al. Anterior cerebral artery emboli in combined intravenous and intra-arterial rtPA treatment of acute ischemic stroke in the IMS I and II trials. AJNR Am J Neuroradiol 2007, 28(10):1890-1894.
92. Arsava E, Ay H, Singhal AB, et al. An infarct volume threshold on early DWI to predict unfavorable clinical outcome. Paper presented at: International Stroke Conference. New Orleans (LA), February 20-22, 2008.
93. Sanak D., Nosal V., Horak D., et al. Impact of diffusion-weighted MRI-measured initial cerebral infarction volume on clinical outcome in acute stroke patients with middle cerebral artery occlusion treated by thrombolysis. Neuroradiology 2006, 48(9):632-639.
94. Hirsch J., Yoo A.J., Nogueira R.G., et al. Case volumes of intra-arterial and intravenous treatment of ischemic stroke in the USA. J Neurointerv Surg 2009, 1(1):27-31.
95. Wolpert S.M., Bruckmann H., Greenlee R., et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993, 14(1):3-13.
96. Lee K.Y., Han S.W., Kim S.H., et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients. Stroke 2007, 38(1):192-193.
97. Smith W.S., Sung G., Saver J., et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008, 39(4):1205-1212.
98. Smith W.S., Sung G., Starkman S., et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005, 36(7):1432-1438.
99. Penumbra Pivotal Stroke Trial Investigators The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009, 40(8):2761-2768.
100. Saver J.L., Albers G.W., Dunn B., et al. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 2009, 40(7):2594-2600.
101. Hakimelahi R, Copen WA, Schaefer PW, et al. A small DWI lesion in the setting of an anterior circulation proximal artery occlusion predicts the presence of a large diffusion-perfusion mismatch. Paper presented at: American Society of Neuroradiology Annual Meeting. Vancouver (BC), May 16-21, 2009.
102. van der Zwan A., Hillen B., Tulleken C.A., et al. A quantitative investigation of the variability of the major cerebral arterial territories. Stroke 1993, 24(12):1951-1959.
103. Jovin T.G., Yonas H., Gebel J.M., et al. The cortical ischemic core and not the consistently present penumbra is a determinant of clinical outcome in acute middle cerebral artery occlusion. Stroke 2003, 34(10):2426-2433.
104. Thomalla G.J., Kucinski T., Schoder V., et al. Prediction of malignant middle cerebral artery infarction by early perfusion- and diffusion-weighted magnetic resonance imaging. Stroke 2003, 34(8):1892-1899.
105. Oppenheim C., Samson Y., Manai R., et al. Prediction of malignant middle cerebral artery infarction by diffusion-weighted imaging. Stroke 2000, 31(9):2175-2181.
106. Lansberg M.G., Thijs V.N., Bammer R., et al. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke 2008, 39(9):2491-2496.
107. Hill M.D., Rowley H.A., Adler F., et al. Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke 2003, 34(8):1925-1931.
108. Hill M.D., Demchuk A.M., Tomsick T.A., et al. Using the baseline CT scan to select acute stroke patients for IV-IA therapy. AJNR Am J Neuroradiol 2006, 27(8):1612-1616.
109. Lev M.H., Segal A.Z., Farkas J., et al. Utility of perfusion-weighted CT imaging in acute middle cerebral artery stroke treated with intra-arterial thrombolysis: prediction of final infarct volume and clinical outcome. Stroke 2001, 32(9):2021-2028.
110. Khatri P., Wechsler L.R., Broderick J.P. Intracranial hemorrhage associated with revascularization therapies. Stroke 2007, 38(2):431-440.
111. Berger C., Fiorelli M., Steiner T., et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic?. Stroke 2001, 32(6):1330-1335.
112. Trouillas P., von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006, 37(2):556-561.
113. Paciaroni M., Agnelli G., Corea F., et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008, 39(8):2249-2256.
114. Fiorelli M., Bastianello S., von Kummer R., et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999, 30(11):2280-2284.
115. Brekenfeld C., Remonda L., Nedeltchev K., et al. Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: assessment of 294 patients treated with urokinase. J Neurol Neurosurg Psychiatry 2007, 78(3):280-285.
116. Larrue V., von Kummer R.R., Muller A., et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001, 32(2):438-441.
117. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997, 28(11):2109-2118.
118. Demchuk A.M., Hill M.D., Barber P.A., et al. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. Stroke 2005, 36(10):2110-2115.
119. Patel S.C., Levine S.R., Tilley B.C., et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001, 286(22):2830-2838.
120. Lansberg M.G., Thijs V.N., Bammer R., et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007, 38(8):2275-2278.
121. Singer O.C., Humpich M.C., Fiehler J., et al. Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. Ann Neurol 2008, 63(1):52-60.
122. Singer O.C., Kurre W., Humpich M.C., et al. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS. Stroke 2009, 40(8):2743-2748.
123. Selim M., Fink J.N., Kumar S., et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke 2002, 33(8):2047-2052.